Related Experiment Video
Updated: Jun 18, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with
Amit G Singal1, Michael L Volk, Donald Jensen
1Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
Insights
Achieving sustained viral response (SVR) significantly reduces liver-related mortality, hepatocellular carcinoma (HCC), and decompensated cirrhosis in hepatitis C virus (HCV) patients. Patients failing treatment face substantial risks without SVR.
Area of Science:
- Hepatology
- Viral Hepatitis Research
- Clinical Outcomes Research
Background:
- Hepatitis C virus (HCV) infection can lead to severe liver complications.
- The long-term outcomes for HCV patients achieving sustained viral response (SVR) versus treatment failure are not fully understood.
- Key outcomes of concern include decompensated cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality.
Purpose of the Study:
- To quantify the incidences of decompensated cirrhosis, HCC, and liver-related mortality in HCV patients.
- To compare these outcomes between patients who achieve SVR and those who experience treatment failure.
- To analyze outcomes specifically in HCV patients with advanced fibrosis.
Main Methods:
- A meta-analysis of observational cohort studies was conducted.
- Studies included HCV patients who failed treatment, with data stratified by SVR status.
- Data extraction was performed by two independent investigators with over 95% agreement.
Main Results:
- The meta-analysis included 26 studies.
- Among HCV patients with advanced fibrosis who failed treatment, significant annual rates of liver-related mortality (2.73%), HCC (3.22%), and hepatic decompensation (2.92%) were observed.
- Patients achieving SVR had significantly lower risks of liver-related mortality (RR 0.23), HCC (RR 0.21), and hepatic decompensation (RR 0.16) compared to treatment failure patients.
Conclusions:
- HCV patients with advanced fibrosis who do not achieve SVR face substantial liver-related morbidity and mortality.
- Achieving SVR dramatically lowers the risk of severe liver complications and death in HCV patients.
- SVR is a critical determinant of improved long-term outcomes for hepatitis C patients.
Background & Aims:
The incidences of decompensated cirrhosis (defined by ascites, hepatic encephalopathy, or bleeding esophageal varices), hepatocellular carcinoma (HCC), and liver-related mortality among patients infected with hepatitis C virus (HCV) who achieve a sustained viral response (SVR), compared with patients who fail treatment (treatment failure), are unclear. We performed a meta-analysis to quantify the incidences of these outcomes.
Methods:
This meta-analysis included observational cohort studies that followed HCV treatment failure patients; data were collected regarding the incidence of decompensated cirrhosis, HCC, or liver-related mortality and stratified by SVR status. Two investigators independently extracted data on patient populations, study methods, and results by using standardized forms. The agreement between investigators in data extraction was greater than 95%. Data analysis was performed separately for studies that enrolled only HCV patients with advanced fibrosis.
Results:
We identified 26 appropriate studies for meta-analysis. Among treatment failure patients with advanced fibrosis, rates of liver-related mortality (2.73%/year; 95% confidence interval [CI], 1.38-4.080), HCC (3.22%/year, 95% CI, 2.02-4.42), and hepatic decompensation (2.92%/year; 95% CI, 1.61-4.22) were substantial. Patients with SVR are significantly less likely than patients who experienced treatment failure to develop liver-related mortality (relative risk [RR], 0.23; 95% CI, 0.10-0.52), HCC (RR, 0.21; 95% CI, 0.16-0.27), or hepatic decompensation (RR, 0.16; 95% CI, 0.04-0.59).
Conclusions:
HCV patients with advanced fibrosis who do not undergo an SVR have substantial liver-related morbidity and mortality. Achieving SVR is associated with substantially lower liver-related morbidity and mortality.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
